We're Keeping An Eye On ITeos Therapeutics' (NASDAQ:ITOS) Cash Burn Rate
ITeos Therapeutics Down Over 29%, on Pace for Largest Percent Decrease Since May 2022 -- Data Talk
ITeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Market-Moving News for September 16th
ITeos Therapeutics Analyst Ratings
Piper Sandler Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $36
ITeos Therapeutics Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab
Express News | Iteos Therapeutics Shares Reverse Course Premarket, Last Down 3.3%
ITeos Therapeutics (ITOS) Receives a Buy From Piper Sandler
H.C. Wainwright Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $46
ITeos Therapeutics Shares Rise on Positive Data From Lung Cancer Study
Wedbush Raises Price Target on ITeos Therapeutics to $25 From $21, Keeps Outperform Rating
Promising Efficacy and Market Potential: ITeos Therapeutics' Combination Therapy Exceeds Phase 2 Expectations
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
Reported Saturday, ITeos Therapeutics Announced Follow-Up Interim Data From GALAXIES Lung-201 Phase 2 Platform Study Sponsored By GSK, For Belrestotug+Dostarlimab Doublet In Previously Untreated, Unresectable, Locally Advanced Or Metastatic PD-L1 High...
Wells Fargo Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $31
Buy Rating Affirmed for ITeos Therapeutics Amid Promising Lung-201 Study Outcomes
GSK, ITeos Lung Cancer Therapy Outperforms Jemperli in Mid-stage Trial
Express News | Iteos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of Galaxies Lung-201 Study of Belrestotug + Dostarlimab in First-Line, Pd-L1 High Non-Small Cell Lung Cancer Patients
ITeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients